Showing 2642 results
- Media Release /Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma The goal of MIGS is to reduce or…
- Media Release /Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU…
- Statement /
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
- Media Release /Sandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,…
- Media Release /2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease New strategy from the Novartis Foundation to accelerate…
- Media Release /Novartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program Novartis improved position in…
- Media Release /Innovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers…
- Media Release /FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster status Entresto (USD 170 million) continued to grow…
- Media Release /Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers…
- Pulse Update /
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 265
- › Next page